Summary
Previous investigations by our group demonstrated the efficacy of single source allogeneic cytotoxic T lymphocytes (CTLs) given multiple times in reducing or curing tumor burden in the rat 9L gliosarcoma model. In this study, the lack of toxicity to normal brain when single source allogeneic CTLs were intracranially administered multiple times is documented. Additionally, the efficacy and lack of toxicity of allogeneic CTLs from multiple sources, each given once is documented. CTLs sensitized to Fischer antigen were prepared from major histocompatibility complex incompatible DA, PVG, Sprague-Dawley and Wistar-Furth rat lymphocytes. CTLs from multiple donors were administered one time each to Fischer rats bearing established 9L tumor at staggered intervals over a two week period and survival was monitored in relation to a sham treated group. Additional groups of nontumor-bearing rats received either multiple source allogeneic CTLs or single source DA anti Fischer CTLs in the same treatment regimen. Histological evaluation of the nontumor-bearing brains receiving either single or multiple source allogeneic CTL infusions showed minimal localized brain damage confined to the cannulation tract. No neuronal loss or inflammatory reaction was seen either adjacent to or remote from the administration site. Brains from the long-term survivors of the tumor-bearing animals showed no residual neoplasm; the instillation site had focal sterile abscesses; gliosis and neuronal loss did not extend into adjacent brain. The safety and potential of chronic, local allogeneic CTL administration, derived from multiple donors, as adjuvant local therapy for brain tumors was demonstrated.
Similar content being viewed by others
References
Fleshner M, Watkins LR, Redd JM, Kruse CA, Bellgrau D: A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplantation 1: 307–312, 1992
Lillehei KO, Mitchell DH, Johnson SD, McCleary EL Kruse CA: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16–23, 1991
Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-De-Masters BK, Bellgrau D: Analysis of interleukin-2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci (USA) 87: 9577–9581, 1990
Kruse CA, Mitchell DH, Kleinschmidt-DeMaster BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO: Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neuro-Oncology 15: 97–112, 1993
Merchant RE, Ellison MD, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neuro-Oncology 8: 173–188, 1990
Hayes RL: The cellular immunotherapy of primary brain tumors. Rev Neurol 148: 454–466, 1992
Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, Okumura K: Establishment of interleukin-2 dependent cytotoxic T lymphocytes cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neuro-Oncol 4: 329–336, 1987
Lillehei KO, Johnson SD, McCleary EL, Mitchell DH, Schiltz PM, Kruse CA: Adjuvant Adoptive Immunotherapy for Pediatric Recurrent Brain Tumors [letter]. Online J Curr Clin Trials [serial online] 1993 Dec 28; 1993: [491 words; 5 paragraphs]
Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau G: Differences in two preparations of interleukin-2 activated lymphocytes generatedin vitro from peripheral blood of patients with malignant brain tumors. Cancer 64: 1629–1637, 1989
Fontana A, Hengartner H, deTribolet N, Weber E: Glioblastoma cells release Interleukin-1 and factors inhibiting interleukin-2-mediated effects. J Immunol 132: 1837–1844, 1984
Dick SJ, Macchi B, Papazoglou S, Oldfield EH, Kornblith PL, Smith BH, Gately MK: Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. Science 220: 739–742, 1983
Lampson LA, Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from histologically normal to that showing different levels of glial tumor involvement. J Immunol 136: 4054–4062, 1986
Kuppner MC, Hamou M-F, deTribolet N: Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas. J Neuroimmunology 29: 229–238, 1990
Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MSJr, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ: Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 15: 201–227, 1981
Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S: Distribution of human Class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 44: 4679–4687, 1984
Gately MK, Glaser M, Dick SJ, Mettetal RW, Kornblith PL:In vitro studies on the cell-mediated immune response to human brain tumor I. Requirement for third party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas. J Natl Cancer Inst 69: 1245–1254, 1982
Redd JM, Lagarde A-C, Kruse CA, Bellgrau D: Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 34: 349–354, 1992
Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, Lillehei KO: Characterization of a continuous human glioma cell line DBTRG-05MG: Growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.In Vitro Cell Dev Biol 28A: 609–614, 1992
Kuppers RC, Ballas ZK, Green WR, Henney CS: Quantitative appraisal of H-2 products in T cell-mediated lysis by allogeneic and syngeneic effector cells. J Immunol 127: 500–504, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kruse, C.A., Schiltz, P.M., Bellgrau, D. et al. Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neuro-Oncol 19, 161–168 (1994). https://doi.org/10.1007/BF01306458
Issue Date:
DOI: https://doi.org/10.1007/BF01306458